Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Fellows’ Forum Case Report: Progressive Weakness and Debilitation with Skin Rash

Usman T. Malik, MBBS  |  Issue: December 2017  |  December 19, 2017

“But we have hope,” we said, “and several treatment options, once we’ve confirmed what you have. We’re hopeful that we can halt the disease process and get you a degree of function back, but we do need some time and more tests.”

More tests. I hated saying that. It’s perhaps the truest statement we have, but who hasn’t hated the truth at least once?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

She brushed a strand away from an irregularly receded hairline. “Will I be able to walk again?”

“I don’t know,” I said. “I hope you might be able to with treatment and significant rehab, but you have significant joint damage from calcium deposits and severe inflammation in your joints. It will be a long road.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

She knew that. She wasn’t stupid. She was a straight A student in high school. She tried to smile at us. “I can do the rehab.”

We discussed treatment options and, bloodwork pending, settled on a tentative one: continuation of low-dose steroids and addition of intravenous immunoglobulins while we sent safety labs for potential use of cyclophosphamide infusions. I signed orders, scheduled a return appointment and escorted her out. I watched her get wheeled away, while she was sitting up as straight as she could muster.

‘Judging by your history & exam, … the rash around your eyes, posterior neck, left arm, the back of your hands & feet; the way your muscles have weakened & wasted so quickly; & these hard lesions,’ I pointed at the ridges of calcinosis around her joints, on her jaw, arms & pressure points, ‘I think you have a form of dermatomyositis.’

Follow-through

As a hospitalist, I disliked not being able to see my patients all the way through treatment and outcome. Even when I made a useful diagnosis, I couldn’t follow my patients past the hospital doors. They went on to their primary care providers, cardiologists, pulmonologists, rheumatologists. Hospital medicine is essential to modern healthcare. It is also quintessentially halfway medicine, incomplete for many of its practitioners. Go to any community (or academic) hospital, and you’ll see how quickly it can become algorithmic. Requesting a consult can become a reflex. Order sets (standardized admission orders) become the quick template you use more and more to make it home for dinner. The excitement of learning and discovering fizzles out, leaving you an empty husk of who you once thought you wanted to be. Sometimes, I suspect the subsequent anhedonia, more than job stress, is the reason so many hospitalists can burn out. I know I did.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsMyositisOther Rheumatic Conditions Tagged with:amyopathyAutoimmune diseaseClinicaldermatomyositisDiagnosisfellowFellowsFellows Foruminflammatory myopathymuscle weaknessoutcomepatient carepolymyopathyRheumatic DiseaserheumatologistrheumatologysymptomTestTreatment

Related Articles
    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Tashatuvango / shutterstock.com

    Myositis-Specific Antibodies Identified

    January 16, 2020

    The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…

    Cancer-Associated Myositis: A Case Report & Review of the Literature

    Cancer-Associated Myositis: A Case Report & Review of the Literature

    February 17, 2019

    Since it was first reported in 1916, a correlation between inflammatory myopathies and cancer has been noted in several studies. Population studies have confirmed this relationship, and the phrase cancer-associated myopathy has entered the vernacular. Over the past decade, research efforts have shifted toward revealing associations between autoantibodies and clinical phenotypes. One subset of auto-antigens…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences